Form 4: Corcept Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Joseph Douglas Lyon, See Remarks of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 1, 2026.
Summary
- Grant/award: acquired 130 Common Stock at $113.38 ($14,739) on September 1, 2026; holds 5,625 after (Direct).
- Grant/award: acquired 130 Common Stock on September 1, 2026; holds 5,755 after (Direct).
- Tax/exercise-price withholding: disposed of 72 Common Stock at $113.38 ($8,163) on September 2, 2026; holds 5,683 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Joseph Douglas Lyon — Officer (See Remarks)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Grant/award | Common Stock | 130 | $113 | $14.7K | 5,625 |
| 2026-09-01 | Grant/award | Common Stock | 130 | — | — | 5,755 |
| 2026-09-02 | Tax/exercise-price withholding | Common Stock | 72 | $113 | $8.2K | 5,683 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Grant/award (130 shares) |
| 2026-09-01 | Grant/award (130 shares) |
| 2026-09-02 | Tax/exercise-price withholding (72 shares) |
Keywords
insider transaction, Form 4, CORT, CORCEPT THERAPEUTICS INC, neutral, Joseph Douglas Lyon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.